Patients have been asking about the RSV vaccine. Respiratory Syncytial Virus can cause severe respiratory disease in adults and has been becoming more prevalent recently. An increase in cases is expected this Fall, so the CDC recommends immunization for high risk individuals over age 60, every adult over 75 years, and all immunocompromised individuals. The vaccine is said to be up to 80% effective in preventing severe lower respiratory tract infections like pneumonia.
RSV vaccine (Pfizer’s Abrysvo or Arexvy by GSK) is made with a live attenuated virus, so there is a potential that it could trigger a flare in some of our patients. However, this vaccine has had few side effects and seems to be well tolerated. We do not have significant experience at Hunter-Hopkins to say whether it is “safe” or not. If the prevalence of RSV is high in your area, or you have a lot of exposure to other people, then highly consider this vaccine.
Unlike the influenza vaccine, RSV does not need to be administered annually. One jab is good for at least 2 years, probably much longer.
The cost of RSV vaccine should be covered by all Medicare programs, but many commercial carriers do not pay for it. Check before getting your vaccination, or it could cost $300 or more out of pocket!